| Methods |
2‐week placebo washout phase; inclusion criteria= postmenopausal women (51‐60 years old) with DBP 91‐105 mm Hg and SBP < 180 mm Hg; 12‐week double‐blind treatment phase, titration‐to‐response after 6 weeks |
| Participants |
Candesartan 8 mg: n=29; mean age=55.1(2.0) years; baseline SBP=159.8(12.3) mm Hg, DBP=100.5(7.2) mm Hg, HR= 76.8(8.9) bpm
Irbesartan 150 mg: n=28; mean age=55.2(2.3) years; baseline SBP=160.6(13.0) mm Hg, DBP=100.9(5.9) mm Hg, HR= 75.9(8.8) bpm
Losartan 50 mg: n=28; mean age=54.7(2.3) years; baseline SBP=160.2(12.1) mm Hg, DBP=99.8(7.1) mm Hg, HR= 76.1(8.6) bpm
Valsartan 80 mg: n=30; mean age=54.8(2.2) years; baseline SBP=161.2(11.9) mm Hg, DBP=101.3(6.7) mm Hg, HR= 77.2(9.2) bpm
Placebo: n=25; mean age=55.1(2.1) years; baseline SBP=159.7(11.5) mm Hg, DBP=100.6(6.1) mm Hg, HR= 75.7(9.1) bpm |
| Interventions |
Candesartan 8 mg once daily;
Irbesartan 150 mg once daily;
Losartan 50 mg once daily;
Valsartan 80 mg once daily;
Placebo;
administered between 8 AM and 9 AM |
| Outcomes |
Trough sitting SBP/DBP using standard mercury sphygmomanometer;
Trough sitting HR |
| Notes |
Used week 6 BP data only; BP change and SD of change not reported, week 6 BP and SD reported, imputed 6‐week SD for SD of change; BP data from Table II, p. 73; Jadad score=4; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
